This result is not nearly as sluggish as the market response suggests.
They booked significant costs, either for future growth (14% R&D increase and new product support +>increased 15% increase in staffing), or none-offs ($12m donation of product and $65m unfavourable forex move, taken above the line).
Most companies would have capitalised some of these expenses, but not CSL; they just expense them outright. Very conservative accounting for profits, which I like.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$241.60 |
Change
0.680(0.28%) |
Mkt cap ! $116.9B | |||
| Open | High | Low | Value | Volume |
| $240.50 | $242.88 | $240.10 | $114.7M | 474.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 539 | $241.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $241.64 | 118 | 2 |
View Market Depth
| Last trade - 16.10pm 14/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |